JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

Search

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

42.91 0.85

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

41.39

Max

43.03

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-19M

-116M

Pardavimai

670K

1M

Pelno marža

-11,216.004

Darbuotojai

437

EBITDA

-19M

-129M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+89.87% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

4.2B

Ankstesnė atidarymo kaina

42.06

Ankstesnė uždarymo kaina

42.91

Naujienos nuotaikos

By Acuity

50%

50%

153 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-21 23:55; UTC

Karštos akcijos

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

2025-10-21 23:49; UTC

Uždarbis

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

2025-10-21 21:40; UTC

Uždarbis

Waste Connections 3Q Revenue Rises

2025-10-21 21:14; UTC

Uždarbis
Pagrindinės rinkos jėgos

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

2025-10-21 21:05; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

2025-10-21 20:57; UTC

Įsigijimai, susijungimai, perėmimai

DraftKings to Launch Prediction Markets Platform

2025-10-21 20:38; UTC

Uždarbis

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

2025-10-21 20:35; UTC

Uždarbis

Capital One 3Q Sales, Profit Jump

2025-10-21 20:32; UTC

Uždarbis

Texas Instruments 3Q Revenue Up on Growth Across End Markets

2025-10-21 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-21 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

2025-10-21 23:39; UTC

Rinkos pokalbiai

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

2025-10-21 23:36; UTC

Rinkos pokalbiai

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

2025-10-21 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Scentre Says This Forms Part of Capital Management Strategy

2025-10-21 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

2025-10-21 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

2025-10-21 21:09; UTC

Rinkos pokalbiai
Uždarbis

Netflix Creators Have Started Using AI in Production -- Market Talk

2025-10-21 20:58; UTC

Rinkos pokalbiai
Uždarbis

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

2025-10-21 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-21 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-10-21 20:43; UTC

Uždarbis

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

2025-10-21 20:41; UTC

Uždarbis

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

2025-10-21 20:33; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

2025-10-21 20:33; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

2025-10-21 20:32; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

2025-10-21 20:31; UTC

Įsigijimai, susijungimai, perėmimai

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

2025-10-21 20:29; UTC

Uždarbis

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

89.87% į viršų

12 mėnesių prognozė

Vidutinis 80.6 USD  89.87%

Aukščiausias 143 USD

Žemiausias 40 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

15

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

153 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat